Skip to Main content Skip to Navigation
Journal articles

C3 glomerulonephritis in a patient treated with anti–PD-1 antibody

Abstract : Immune checkpoint inhibitors (ICIs) have dramati-cally transformed the treatment of solid tumors. ICIsinduce an immune response against tumoral cells as aresult of the removal of T-cell inhibition [1]. The logicalcounterpart of turning off T-cell inhibitory mechanismsis the onset of immune-related adverse events (irAEs)that affect different organs. Although the most frequentrenal irAE is acute interstitial nephritis [2], we report afirst case of C3 glomerulonephritis (GN) associated withthe use of an antieProgrammed Cell Death 1 (PD-1)humanised antibody.
Complete list of metadatas

https://www.hal.inserm.fr/inserm-02449014
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Wednesday, January 22, 2020 - 4:03:35 PM
Last modification on : Saturday, March 28, 2020 - 1:55:43 AM

Identifiers

Citation

Simon Ville, Christine Kandel-Aznar, Veronique Fremeaux-Bacchi, Fadi Fakhouri. C3 glomerulonephritis in a patient treated with anti–PD-1 antibody. European Journal of Cancer, Elsevier, 2020, 125, pp.46-48. ⟨10.1016/j.ejca.2019.11.011⟩. ⟨inserm-02449014⟩

Share

Metrics

Record views

86